Peer Perspectives: Advances in Macular Telangiectasia Type 2 Care

Our experts walk through the hallmark features and diagnostic challenges of MacTel.

By: Sophie J. Bakri, MD, MBA, Roger A. Goldberg, MD, MBA

Retinal Physician June 11, 2025

Clinical Report: Advances in Macular Telangiectasia Type 2 Care

Overview

This report discusses recent advancements in the diagnosis and management of Macular Telangiectasia Type 2 (MacTel). Key findings include the importance of multimodal imaging techniques and the introduction of new therapeutic options, including the first disease-modifying therapy.

Background

Macular Telangiectasia Type 2 is a slowly progressing bilateral disease that primarily affects Müller glial cells, leading to neurodegeneration and visual impairment. Accurate diagnosis is crucial as it can be confused with other retinal diseases, necessitating advanced imaging techniques for differentiation. Recent advancements in understanding the disease's pathophysiology and treatment options underscore the need for ongoing education among healthcare professionals.

Data Highlights

No numerical data provided in the source material.

Key Findings

MacTel is primarily a neurodegenerative disease affecting Müller glial cells, leading to secondary photoreceptor loss.
Multimodal imaging, including OCT and fluorescein angiography, is essential for accurate diagnosis.
Recent studies highlight the role of Müller-cell dysfunction and serine-pathway derangements in the disease's pathophysiology.
Anti-VEGF therapy remains the standard for proliferative forms of MacTel, while the efficacy in non-proliferative cases is limited.
The FDA approved revakinagene taroretcel-lwey (Encelto), the first disease-modifying therapy for MacTel type 2, showing slowed progression of ellipsoid zone loss.

Clinical Implications

Healthcare professionals should utilize multimodal imaging for the accurate diagnosis of MacTel and remain updated on emerging therapies. The introduction of disease-modifying treatments represents a significant advancement in managing this condition, emphasizing the importance of early detection and intervention.

Conclusion

Advancements in the understanding and management of MacTel type 2 are crucial for improving patient outcomes. Continued research and education will enhance diagnostic accuracy and therapeutic options for this challenging condition.

PentaVision

Retinal Physician